FPAS
RCKT icon

Focus Partners Advisor Solutions’s Rocket Pharmaceuticals RCKT Stock Holding History

Focus Partners Advisor Solutions’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$40.6K Sell
11,877
-12,776
-52% -$42.5K ﹤0.01% 1229
2026
Q1 		$88.3K Buy
+24,653
New +$98K ﹤0.01% 1204

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Focus Partners Advisor Solutions's RCKT Position: Q2 2026 in Review

Focus Partners Advisor Solutions reduced its Rocket Pharmaceuticals (RCKT) stake by 52% in Q2 2026, selling an estimated $42.5K and leaving 11,877 shares worth $40.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1229.

Focus Partners Advisor Solutions first reported a position in RCKT in Q1 2026 and has held it in 2 quarters since. The position peaked at $88.3K in Q1 2026. 180 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.

  • Focus Partners Advisor Solutions held 11,877 shares of Rocket Pharmaceuticals worth $40.6K as of Q2 2026.
  • Focus Partners Advisor Solutions sold 12,776 Rocket Pharmaceuticals shares in Q2 2026, an estimated $42.5K.
  • Rocket Pharmaceuticals made up ﹤0.01% of Focus Partners Advisor Solutions's portfolio in Q2 2026, its #1229 holding.
  • Focus Partners Advisor Solutions first reported a position in Rocket Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Focus Partners Advisor Solutions's Rocket Pharmaceuticals position peaked at $88.3K in Q1 2026.
  • 180 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.

Based on Focus Partners Advisor Solutions's 13F filing for Q2 2026, filed 6 Aug 2026.